Pharmaron
China clinical platform within a global development network, with operations linked to SMO and recruitment teams. Distinguish China delivery from the group’s US and UK early-phase facilities.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
34 matching companies
China clinical platform within a global development network, with operations linked to SMO and recruitment teams. Distinguish China delivery from the group’s US and UK early-phase facilities.
China-origin global clinical CRO with a disclosed Chinese investigator network and cross-regional development services. Historical offering documents reference IITs; confirm current indication-specific IIT staffing and scope.
Offers clinical operations and China–US registration services, with US development through BioTrialMed. For inbound China work, confirm local delivery, English communication and quality responsibilities separately.
Clinical and laboratory platform with China and North America operations, including early-phase clinical services and biometrics. Assess early development fit separately from full-service registrational trial management.
APAC-origin international CRO with disclosed China teams, offices and site partnerships. Relevant to biotech China delivery comparisons; IIT support requires project-level confirmation.
Discloses China clinical operations, biometrics, regulatory and safety services, with explicit China IIT support for international developers, including cell and gene therapies. A US subsidiary and international partner network support cross-border engagement.
China-origin global CRO. Its China service page describes Phase I–IV work, site start-up, operations and biometrics for local and global sponsors. Global trial experience does not establish a specific IIT track record.
International CRO incorporating China-origin dMed. Discloses China operational strength and connected development between China, the US and Europe.
Cross-border CRO with China operations. Team biographies reference Phase I–IV and IIT experience. Staff experience is not proof of company-level IIT delivery; verify the contracting entity and China project lead.
China clinical CRO with biometrics and trial management capabilities. A Medidata partnership announcement supports its clinical technology and data-standardization approach; confirm international sponsor references and IIT staffing directly.
JOINN’s corporate disclosures include clinical trials and pharmacovigilance. Verify the clinical team and contracting entity; group GLP toxicology credentials do not establish clinical GCP execution capability.
China full-service clinical CRO disclosing a Shanghai entity and US subsidiary, targeting overseas-sponsored China studies. Confirm current staffing, sponsor references and delivery entity.
China clinical CRO with a Medidata partner profile and a Micron alliance announcement supporting international collaboration. Proswell is a separate company from GCP ClinPlus.
China-origin CRO disclosing international branches and operations, regulatory, writing and biometrics services. Public materials describe China–US and multi-country submissions; confirm inbound China and IIT experience.
China clinical CRO whose English site describes domestic and overseas clients and hospital-initiated research involving international sites. This supports investigator-led experience, with current commercial IIT scope to confirm.
SIIP’s official business page identifies Shanghai Yilinsi clinical services covering Phase I–IV, human PK, bioequivalence and international multicentre studies. Confirm English project staffing and recent overseas sponsor references.
China clinical platform formerly associated with WuXi AppTec, now part of Emerald Clinical and operating as Hongyi Clinical. Consolidated with historical WuXi Clinical rather than counted as a separate current WuXi subsidiary.
International CRO China platform. Official materials discuss China IIT versus IND pathways and local CRO support for IITs. IQVIA and KunTuo are presented as one group platform to avoid double counting.
International full-service CRO with China delivery and published early-phase partner-site information. Confirm the actual team, indication and protocol rather than assuming global coverage establishes IIT fit.
International CRO disclosing China/APAC clinical operations and a Beijing central laboratory. Contract clinical operations and laboratory scope separately; current IIT support is not established by the reviewed sources.
Thermo Fisher’s clinical research business. Its China page describes local regulatory, linguistic and operational support for development programs.
International CRO with official China locations and a multinational oncology case study. A case example does not establish experience across every indication or IIT pathway.
International clinical development platform with officially listed Beijing and Shanghai offices. Assess integrated global delivery separately from local IIT scope and confirm current resources.
International full-service CRO with official evidence of Shanghai and Beijing clinical teams. Confirm current China full-service scope and IIT availability directly.
Coverage expands from sourced records; this database does not claim all biopharma companies.